Nwam LLC bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 14,926 shares of the exchange traded fund’s stock, valued at approximately $1,475,000.
Other hedge funds have also recently modified their holdings of the company. Tidemark LLC lifted its position in shares of SPDR S&P Biotech ETF by 101.5% during the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock worth $39,000 after buying an additional 199 shares in the last quarter. Quintet Private Bank Europe S.A. bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth approximately $40,000. ORG Partners LLC bought a new position in shares of SPDR S&P Biotech ETF during the 2nd quarter worth approximately $40,000. ORG Wealth Partners LLC bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth approximately $44,000. Finally, Howe & Rusling Inc. bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth approximately $49,000.
SPDR S&P Biotech ETF Stock Up 2.1 %
SPDR S&P Biotech ETF stock opened at $96.24 on Friday. The company’s 50 day moving average price is $98.44 and its two-hundred day moving average price is $96.23. SPDR S&P Biotech ETF has a 52 week low of $71.99 and a 52 week high of $105.47. The stock has a market cap of $7.34 billion, a P/E ratio of 11.47 and a beta of 1.11.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Tesla Investors Continue to Profit From the Trump Trade
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Best Aerospace Stocks Investing
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.